CN101147742A - Medicinal composition containing licorice total flavone and alooerine - Google Patents
Medicinal composition containing licorice total flavone and alooerine Download PDFInfo
- Publication number
- CN101147742A CN101147742A CNA2006101529484A CN200610152948A CN101147742A CN 101147742 A CN101147742 A CN 101147742A CN A2006101529484 A CNA2006101529484 A CN A2006101529484A CN 200610152948 A CN200610152948 A CN 200610152948A CN 101147742 A CN101147742 A CN 101147742A
- Authority
- CN
- China
- Prior art keywords
- aloperine
- radix glycyrrhizae
- total flavones
- alooerine
- composition containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000011949 flavones Nutrition 0.000 title claims abstract description 30
- 229930003944 flavone Natural products 0.000 title claims abstract description 29
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 title abstract description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 title abstract description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 title abstract description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 title abstract description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 title abstract description 3
- 150000002212 flavone derivatives Chemical class 0.000 title abstract description 3
- 229940010454 licorice Drugs 0.000 title abstract description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 title abstract 2
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 12
- 230000006793 arrhythmia Effects 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 3
- 230000003612 virological effect Effects 0.000 claims abstract description 3
- SKOLRLSBMUGVOY-GBJTYRQASA-N aloperine Chemical compound C1=C2CCCN[C@H]2[C@H]2CN3CCCC[C@@H]3[C@@H]1C2 SKOLRLSBMUGVOY-GBJTYRQASA-N 0.000 claims description 33
- PCTYDEAPIWWHMV-UHFFFAOYSA-N aloperine Natural products C1CCN2CC3CC(CC4CCCNC34)C2C1 PCTYDEAPIWWHMV-UHFFFAOYSA-N 0.000 claims description 33
- 150000002213 flavones Chemical class 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 8
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 8
- 229940039750 aconitine Drugs 0.000 description 8
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 7
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 6
- 229960004949 glycyrrhizic acid Drugs 0.000 description 6
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 6
- 235000019410 glycyrrhizin Nutrition 0.000 description 6
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 239000004378 Glycyrrhizin Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 4
- 244000166550 Strophanthus gratus Species 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 4
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 4
- 229960003343 ouabain Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 229930194248 Licoflavone Natural products 0.000 description 3
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- -1 flavone compound Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 3
- 235000008718 isoliquiritigenin Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- PGCKDCPTJAQQSQ-UHFFFAOYSA-N Isolicoflavonol Chemical compound C1=C(O)C(CC=C(C)C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 PGCKDCPTJAQQSQ-UHFFFAOYSA-N 0.000 description 2
- YNWXJFQOCHMPCK-UHFFFAOYSA-N Isoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-UHFFFAOYSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 2
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- NZYSZZDSYIBYLC-UHFFFAOYSA-N glycycoumarin Chemical compound C=1C=2C(OC)=C(CC=C(C)C)C(O)=CC=2OC(=O)C=1C1=CC=C(O)C=C1O NZYSZZDSYIBYLC-UHFFFAOYSA-N 0.000 description 2
- NPQWZAAWZLVQIZ-UHFFFAOYSA-N glycycoumarin Natural products COc1cc2OC(=O)C(=Cc2c(O)c1CC=C(C)C)c3ccc(O)cc3O NPQWZAAWZLVQIZ-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- YNWXJFQOCHMPCK-LXGDFETPSA-N isoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-LXGDFETPSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- KAZSKMJFUPEHHW-UHFFFAOYSA-N (2E)-3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hdyroxyphenyl)-2-propen-1-one Natural products COC1=CC(O)=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- KAZSKMJFUPEHHW-DHZHZOJOSA-N Licochalcone A Chemical compound COC1=CC(O)=C(C(C)(C)C=C)C=C1\C=C\C(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-DHZHZOJOSA-N 0.000 description 1
- IUCVKTHEUWACFB-UHFFFAOYSA-N Licochalcone A Natural products COC1=CC=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 IUCVKTHEUWACFB-UHFFFAOYSA-N 0.000 description 1
- MOBCUWLJOZHPQL-UHFFFAOYSA-N Licopyranocoumarin Chemical compound C=1C=2C(OC)=C3CCC(C)(CO)OC3=CC=2OC(=O)C=1C1=CC=C(O)C=C1O MOBCUWLJOZHPQL-UHFFFAOYSA-N 0.000 description 1
- MOBCUWLJOZHPQL-OAQYLSRUSA-N Licopyranocoumarin Natural products O(C)c1c2c(OC(=O)C(c3c(O)cc(O)cc3)=C2)cc2O[C@](CO)(C)CCc12 MOBCUWLJOZHPQL-OAQYLSRUSA-N 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001145009 Sophora alopecuroides Species 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000004873 systolic arterial blood pressure Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medicinal composition containing licorice total flavone and alooerine. It can be used for curing arrhythmia and viral diseases due to various causes.
Description
Technical field
The present invention relates to a kind of Pharmaceutical composition that contains Radix Glycyrrhizae total flavones and aloperine, belong to medical technical field.
Background technology
China is familiar with in the world and studies Radix Glycyrrhizae country the earliest.It is promptly on the books in the Shennong's Herbal of book that the Eastern Han Dynasty becomes, and it is classified as top grade, and after this successive dynasties book on Chinese herbal medicine is all on the books to Radix Glycyrrhizae.Radix Glycyrrhizae is the pulse family glycyrrhiza genus, and licoflavone (GB) is one of component of Radix Glycyrrhizae, according to available data, has separated obtaining more than 100 kind of flavone compound both at home and abroad from Radix Glycyrrhizae.Result of study shows that GB2mg/kg can obviously resist aconitine 20 μ g/kg, BaCl
22mg/kg and ligation ramus descendens anterior arteriae coronariae sinistrae bring out the ventricular arrhythmia of rat.50mg/kg～100mg/kg Radix Glycyrrhizae total flavones can prolong the incubation period of the mice arrhythmia that aconitine brings out, reduce the mice ventricular fibrillation positive rate that chloroform brings out, 25mg/kg～50mg/kg Radix Glycyrrhizae total flavones can increase ouabain and bring out that ventricular premature contraction, chamber speed appear in Cavia porcellus, quiver in the chamber and heartbeat stops used dosage, illustrates that Radix Glycyrrhizae total flavones has anti-arrhythmia effect.Hu Xiaoying etc. studies show that Radix Glycyrrhizae total flavones all has antagonism to the arrhythmia that aconitine, chloroform, ouabain bring out, and are similar to the effect of Radix Glycyrrhizae, and the main effective ingredient of antiarrhythmic may be flavone compound in the prompting Radix Glycyrrhizae.
It is reported: the arrhythmia that chloroform brings out may be relevant to the effect of endogenous catecholamine with its sensitization heart; Ouabain directly suppresses Na
+-K
+The ATP enzyme causes Ca in the myocardial cell
2+Over loading; Aconitine can make Na
+Channel opener quickens Na
+In stream, impel the cell membrane depolarization, quicken the self-disciplining of Pacemaker cardiac, form the polyphyly ectopic rhythm, shorten refractory stage and cause arrhythmia.The arrhythmia that Radix Glycyrrhizae total flavones brings out them all has antagonism.
Modern pharmacological research proves that glycyrrhizin and isoliquiritigenin have the ability of very strong inhibition HIV virus.Glycycoumarin belongs to the derivant of osajin, and multiple licoflavone constituents such as licopyranocoumarin can suppress the inductive giant cell of HIV and form, and does not see cytotoxicity.
The Japan scholar is resulting phenolic constituent (comprising flavones ingredient) from the research of Radix Glycyrrhizae tannin active component, strengthened the antagonism of HIV (human immunodeficiency virus) (HIV), wherein demonstrated the effect of HIV inhibition of proliferation during 2 kinds of new liquorice chalcone low concentrations ATLIK (deriving from adult T-cell leukemia patient's cell strain).Licochalcone A, isolicoflavonol, glycycoumarin, flavone compounds such as glycyrhisoflavone and licopyrancoumarin are at 20 μ gmL
-1The time, to the Mol2t24 cell inductive Piant cell HIV stronger inhibitory action is arranged, and glycyrrhizin is at 500 μ gmL
-1Inhibitory action is just arranged.Modal monomer component liquiritin in the licorice, liquiritigenin, isoliquiritin and isoliquiritigenin have inhibitory action to the new city HIV (human immunodeficiency virus).Japan professor Tian Tuonan difficult to understand report, it is 25 times of glycyrrhizin to the propagation inhibition ability of HIV (human immunodeficiency virus) that 3 kinds of flavones ingredients are arranged in the Radix Glycyrrhizae.The ingredient of crossing the treatment acquired immune deficiency syndrome (AIDS) of limit and invention such as great mainly contains licoflavone class (glycyrrhizin, isoliquiritigenin, liquiritin, isoliquiritin), its HIV (human immunodeficiency virus)-resistant activity is 15～100 times of glycyrrhizic acid, and proved that the existence of glycyrrhizic acid does not influence the pharmacological effect of flavone, caused the extensive attention of Chinese scholars.
(Aloperine ALO) is isolated alkaloid from cassia leguminous plant Herba Sophorae alopecuroidis (Sophora alopecuroides) to aloperine.Discover the instantaneous rising of heart rate, systolic arterial pressure, diastolic pressure, left indoor pressure and left indoor pressure and the decrease speed that can obviously reduce cat behind the intravenous injection aloperine 10mg/kg in the 1min, but that this effect of aloperine can recover at short notice all except that heart rate is normal.Rat ventricular that the aloperine of same dosage brings out aconitine and the death that causes have significant protective effect, rat was obviously prolonged because of the death time that the injection aconitine causes, and the accumulative total using dosage of aconitine significantly increase.Aloperine 10,5mg/kg also have significant protective effect to the typical ischemic arrhythmia that the left anterior descending branch of ligation rat coronary artery causes.And the aloperine of 100 μ mol/L is to isolated rat heart muscle Ca
2+The contractility that triggers increases and heart rate accelerates not have the obvious suppression effect.
Quiet notes aloperine 10mg/kg, can significantly increase the tolerance that guinea pig heart is poisoned to ouabain, and cause premature beat and dead consumption, increase to 137.9 ± 20.8 μ g/kg and increase to 249.1 ± 40.2 μ g/kg by 102.9 ± 16.2 μ g/kg respectively by 199.5 ± 33.1 μ g/kg; Aloperine 10mg/kg can obviously resist the arrhythmia that suction chloroform and quiet notes epinephrine 50 μ g/kg bring out rabbit; Aloperine 10mg/kg, the rat arrhythmia that can obviously prevent aconitine 201 μ g/kg to be brought out; Aloperine 10mg/kg can significantly reduce CaCl
2Rate and mortality rate quiver in the chamber of rat due to the 130mg/kg; Lumbar injection aloperine 10mg/kg makes mice suck chloroform after 15 minutes, with the normal saline group relatively, its chamber incidence rate of quivering drops to 33.3% by 94.4% of matched group, the difference highly significant; Aloperine 10mg/kg can make the heart rate of rat, Cavia porcellus and rabbit obviously slow down, and can obviously resist the gaining rate effect of isoproterenol; In guinea-pig heart room specimen, also observe aloperine and can obviously resist the effect that isoproterenol increases the atrium self-disciplining.In a word, aloperine arrhythmia that multiple reason is caused has the certain protection effect.
Result of study shows that aloperine has tangible anti-enterovirus effect, to coxsackie B group 3 type (CB
3V), poliovirus III type (JPVIII), newtype enteroviru 71 type (E
71V), COxsackie A
16Virus (CA
16V) inhibition logarithm can reach 2.0～3.0, and the protective rate of pair cell reaches as high as 94.1%.Prove that through external quantitative experiment (15.62mg/L) still had antivirus action when aloperine was diluted to 1: 64 times.By detection, find that aloperine not only has the effect of direct inactivation of viruses, and inhibitory action is all arranged being adsorbed in cell surface and entering intracellular virus to its antivirus action link.
Summary of the invention
On the basis of summing up document, we have invented a kind of Pharmaceutical composition that contains Radix Glycyrrhizae total flavones and aloperine, are used for the treatment of arrhythmia and viral disease that a variety of causes causes, can play synergism, reach better therapeutic.
The present invention is specific as follows: 1～99 part of Radix Glycyrrhizae total flavones, 99～1 parts of aloperines, specifically, 1～9 part of Radix Glycyrrhizae total flavones, 9～1 parts of aloperines, its preferred version: Radix Glycyrrhizae total flavones: aloperine=3: 2.
Following examples explanation the present invention, but do not limit the present invention in any way.
Embodiment 1 liquid drugs injection (1000)
Prescription: Radix Glycyrrhizae total flavones 18g aloperine 12g glycerol 400ml water for injection adds to 2000ml
With Radix Glycyrrhizae total flavones, aloperine and glycerol mix homogeneously, add water for injection, with the pH value of hydrochloric acid solution regulator solution, make 2000ml altogether, filtration, embedding are pacified in the bottle in 2ml, sterilization (115 ℃, 30 minutes), promptly.
Embodiment 2 liquid drugs injections (1000)
Prescription: Radix Glycyrrhizae total flavones 45g aloperine 30g glycerol 1000ml water for injection adds to 5000ml
With Radix Glycyrrhizae total flavones, aloperine and glycerol mix homogeneously, add water for injection, with the pH value of hydrochloric acid solution regulator solution, make 5000ml altogether, filtration, embedding are pacified in the bottle in 5ml, sterilization (115 ℃, 30 minutes), promptly.
Claims (4)
1. Pharmaceutical composition that contains Radix Glycyrrhizae total flavones and aloperine is characterized in that it is made up of for 99～1 parts 1～99 part of Radix Glycyrrhizae total flavones, aloperine;
2. according to claim 1, a kind of Pharmaceutical composition that contains Radix Glycyrrhizae total flavones and aloperine is characterized in that it is made up of for 9～1 parts 1～9 part of Radix Glycyrrhizae total flavones, aloperine;
3. according to claim 1, a kind of Pharmaceutical composition that contains Radix Glycyrrhizae total flavones and aloperine is characterized in that it is made up of for 2 parts 3 parts of Radix Glycyrrhizae total flavoness, aloperine;
4. according to claim 1, a kind of Pharmaceutical composition that contains Radix Glycyrrhizae total flavones and aloperine is characterized in that it is used for the treatment of arrhythmia and viral disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101529484A CN101147742A (en) | 2006-09-21 | 2006-09-21 | Medicinal composition containing licorice total flavone and alooerine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101529484A CN101147742A (en) | 2006-09-21 | 2006-09-21 | Medicinal composition containing licorice total flavone and alooerine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101147742A true CN101147742A (en) | 2008-03-26 |
Family
ID=39248514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101529484A Pending CN101147742A (en) | 2006-09-21 | 2006-09-21 | Medicinal composition containing licorice total flavone and alooerine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101147742A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832814A (en) * | 2016-04-26 | 2016-08-10 | 宁夏医科大学 | General flavone with effect of treating diabetic mellitus, as well as preparation method and application thereof |
-
2006
- 2006-09-21 CN CNA2006101529484A patent/CN101147742A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832814A (en) * | 2016-04-26 | 2016-08-10 | 宁夏医科大学 | General flavone with effect of treating diabetic mellitus, as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101357219B (en) | Medicine for treating chronic hepatitis B | |
| CN1872105A (en) | Application of holly and extractive in preparing medication for anti virus | |
| Bao et al. | Traditional Chinese medicine formulation Huangqi Jianzhong Tang improves cardiac function after myocardial infarction in rats | |
| WO2007059685A1 (en) | Astragalus calycosin with the function of resisting coxackievirus | |
| KR19990015612A (en) | Hepatitis C Therapeutic Composition Containing Mixed Extracts of Hwangbaekpi and Matari Plants | |
| CN101147742A (en) | Medicinal composition containing licorice total flavone and alooerine | |
| CN101406613B (en) | Use of Chinese medicinal composition in preparing medicament for treating vital myocarditis | |
| CN101904935A (en) | Chinese medicinal composition for improving immunity of organisms, tonifying middle-jiao and qi and treating canine distemper | |
| CN103055122B (en) | The medicine and preparation method thereof of restenosis after prevention percutaneous transluminal coronary stent implantation | |
| US20080102140A1 (en) | Use of solidago virgaurea in the treatment and prevention of viral infections | |
| CN102225155B (en) | Medicament composition for treating pulmonary fibrosis | |
| CN100363034C (en) | Chinese medicinal composition for treating ascites due to cirrhosis | |
| CN100569247C (en) | A traditional Chinese medicine composition for strengthening the body and benefiting the liver, its preparation and application | |
| CN105073124A (en) | Pharmaceutical composition for treating acquired immune deficiency syndrome and method for preparing same | |
| CN101057906B (en) | Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application | |
| CN110840969B (en) | A kind of traditional Chinese medicine composition for treating hepatitis C and its application | |
| CN103585291B (en) | Application of herba delphinii extract in preparation of drugs treating AIDS | |
| CN1247222C (en) | Pharmaceutical composition for treating AlDS | |
| CN107669695A (en) | Application of the icariside II in anti-hepatitis B virus product is prepared | |
| CN110179785B (en) | Application of widmanone in preparation of medicine for treating or preventing hand-foot-and-mouth disease | |
| CN101129400B (en) | Application of Polysaccharides from Polygonatum Polygonatum in Preparation of Drugs for Treating Coronary Heart Disease | |
| CN104161800B (en) | It is a kind of to be used to treat Chinese medicine composition of angiocardiopathy and preparation method thereof | |
| Hau et al. | Combined therapy of mitomycin C and Chinese medical herbs on experimental liver cancer | |
| Yan et al. | Investigation of therapeutic effect of Longchai Formula Granule on chronic hepatitis B patients: A double-blind, controlled and randomized clinical trial | |
| CN104306437B (en) | A kind of for Chinese medicinal granular formulation treating cardiovascular disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Hanteng Document name: Written notice of preliminary examination of application for patent for invention |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080326 |